Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)

Next Previous
X
Search
Trial Profile

A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tisagenlecleucel (Primary) ; Tocilizumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Nov 2022 Results (n=206) assessing the influence of household poverty and neighborhood social determinants on outcomes from CAR T-cell therapy for relapsed/refractory leukemia from (NCT01626495; NCT02435849 ; NCT02374333; NCT02228096; NCT02906371) clinical trials and commercial tisagenlecleucel from 2012 to 2020, published in the Blood.
    • 07 Jun 2022 Results assessing impact of socioeconomic status on survival after CD19 CART therapy using data from CD19 CART clinical trials (NCT01626495, NCT02435849, NCT02374333, NCT02228096, NCT02906371) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top